Clinical Trial Update: Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Spiriva (tiotropium bromide) assessing FEV1 in chronic obstructive pulmonary disease; the SAFE-Portugal study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED